US declares USD 41 million to India as additional Covid-19 assistance

USAID’s assistance will support access to Covid-19 testing, pandemic-related mental health services, timely referrals to medical services, and access to healthcare in remote areas

The US has announced an additional $ 41 million assistance to help India respond to the Covid-19 pandemic and strengthen the country’s preparedness for the future health emergencies, taking the total aid to more than $ 200 million.

In April and May, India struggled with the second wave of the Covid-19 pandemic with more than 3,00,000 daily new cases. Hospitals were reeling under a shortage of medical oxygen and beds.

“India came to the assistance of the United States during this country’s time of need, and now the United States stands with the people of India as they continue to battle the Covid-19 pandemic,” the US Agency for International Development said on Monday.

USAID announced an additional $ 41 million in support to help India respond to the Covid-19 pandemic and strengthen the country’s preparedness for Covid-19 and future health emergencies.

USAID’s assistance will support access to Covid-19 testing, pandemic-related mental health services, timely referrals to medical services, and access to healthcare in remote areas, the independent agency of the US federal government primarily responsible for administering civilian foreign aid and development assistance said.

Through this additional funding, USAID will continue to partner with India to strengthen healthcare supply chains and electronic health information systems, support its vaccination efforts, and mobilize and coordinate private sector relief, it said. USAID has contributed more than $200 mn for India’s Covid-19 relief and response efforts since the pandemic began, including more than $50 mn in emergency supplies and training for more than 2,14,000 frontline health workers on infection prevention and control, benefitting more than 42 mn Indians, according to a media release.

Chinese vaccine safe for children, adolescents: Lancet

Two doses of the China-made Covid-19 vaccine, CoronaVac, are safe and produce a strong antibody response among children and adolescents aged 3-17 years, according to a study published in The Lancet Infectious Diseases journal. The phase 1/2 trial on 550 young people found that over 96 per cent of children and adolescents who received two doses of the vaccine by Sinovac, developed antibodies against SARS-CoV-2, the virus that causes Covid-19. Most reactions were mild or moderate, with pain at the injection site the most commonly reported symptom, the researchers said.

Sputnik V vaccine records 97.8 pc efficacy in UAE

The Russian Direct Investment Fund (RDIF) on Tuesday announced that the efficacy of its Covid-19 vaccine Sputnik V in the United Arab Emirates (UAE) was confirmed at 97.8 per cent among over 81,000 people.

Australia offers all adults AstraZeneca

Australia is offering AstraZeneca to all adults in a bid to rapidly ramp up sluggish vaccination rates as more of the country on Tuesday locked down against the spread of Covid-19. The government late Monday agreed to indemnify doctors who administer the AstraZeneca vaccine that has been blamed for at least two fatalities from a rare blood clot complication in Australia since April.

1,54,960
No. of new cases reported globally in the past 24 hours

18,10,07,816
Total no. of cases worldwide

39,27,222
Total no. of deaths worldwide

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!